This is the company's first solution to treat Early Onset Scoliosis patients, specifically those associated with or at risk of Thoracic Insufficiency Syndrome.
Bone Biologics is focusing development of a bone graft substitute for bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications.
The policy expansion represents 2.3+ million covered lives across Tennessee and includes a positive coverage recommendation for 1- and 2-level lumbar TDR